Literature DB >> 12394954

Prognosis of hematologic malignancies does not predict intensive care unit mortality.

Paul B Massion1, Alain M Dive, Chantal Doyen, Pierre Bulpa, Jacques Jamart, André Bosly, Etienne Installé.   

Abstract

OBJECTIVE: To evaluate the correlation between specific prognosis of hematologic malignancies on the one hand and intensive care unit and hospital mortality in critically ill patients with hematologic malignancies on the other hand.
DESIGN: Observational study during a 10-yr period.
SETTING: A 22-bed medical-surgical intensive care unit. PATIENTS: A total of 84 consecutive patients with nonterminal hematologic malignancies with medical complications requiring intensive care.
INTERVENTIONS: None. MEASUREMENTS: Demographic factors, acute physiology and organ dysfunction scores, microbiology, therapeutic support, and hematologic factors data on admission and during the intensive care unit stay were collected, together with mortality follow-up. Based on specific-disease prognostic factors and related published survival curves, the prognosis of hematologic malignancies was assessed and defined as good, intermediate, or poor according to a 3-yr survival probability of >50%, 20-50%, or <20%, respectively. MAIN
RESULTS: Prognosis of hematologic malignancies does not predict intensive care unit or hospital mortality and almost reaches significance for 6-mo mortality (53%, 71%, and 84% rate for patients with good, intermediate, and poor prognosis, respectively, p =.058), but it determines long-term survival (p =.008). Intensive care unit, hospital, and 6-mo overall mortality rates were 38%, 61%, and 75%, respectively. Using multivariate analysis, intensive care unit mortality was best predicted on admission by respiratory failure and fungal infection, whereas hospital mortality was predicted by the number of organ failures, the bone marrow transplant status, and the presence of fungal infection. The Acute Physiology and Chronic Health Evaluation II and the Simplified Acute Physiology Score II had no prognostic value, whereas the difference of the Multiple Organ Dysfunction Score between at the time of admission and at day 5 allowed quick prediction of hospital mortality. Diseases with the poorest 6-mo prognosis were acute myeloid leukemia and non-Hodgkin lymphoma. CONCLUSION The severity of the underlying hematologic malignancies does not influence intensive care unit or hospital mortality. Short-term prognosis is exclusively predicted by acute organ dysfunctions and by a pathogen's aggressiveness. Therefore, reluctance to admit patients with nonterminal hematologic malignancies to the intensive care unit based only on the prognosis of their underlying hematologic malignancy does not seem justified.

Entities:  

Mesh:

Year:  2002        PMID: 12394954     DOI: 10.1097/00003246-200210000-00014

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  48 in total

1.  Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience.

Authors:  Peter Schellongowski; Thomas Staudinger; Michael Kundi; Klaus Laczika; Gottfried J Locker; Andja Bojic; Oliver Robak; Valentin Fuhrmann; Ulrich Jäger; Peter Valent; Wolfgang R Sperr
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

2.  The intensive care support of patients with malignancy: do everything that can be done.

Authors:  Elie Azoulay; Bekele Afessa
Journal:  Intensive Care Med       Date:  2005-11-25       Impact factor: 17.440

Review 3.  Diagnostic strategy in cancer patients with acute respiratory failure.

Authors:  Elie Azoulay; Benoît Schlemmer
Journal:  Intensive Care Med       Date:  2006-04-29       Impact factor: 17.440

Review 4.  The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.

Authors:  Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares
Journal:  Intensive Care Med       Date:  2017-07-19       Impact factor: 17.440

5.  Comparison of three severity scores for critically ill cancer patients.

Authors:  Peter Schellongowski; Michael Benesch; Thomas Lang; Friederike Traunmüller; Christian Zauner; Klaus Laczika; Gottfried J Locker; Michael Frass; Thomas Staudinger
Journal:  Intensive Care Med       Date:  2003-11-04       Impact factor: 17.440

6.  Management of Acute Respiratory Failure in Patients With Hematological Malignancy.

Authors:  Rakesh Vadde; Stephen M Pastores
Journal:  J Intensive Care Med       Date:  2016-07-07       Impact factor: 3.510

7.  Outcome and prognostic indicators of patients with hematopoietic stem cell transplants admitted to the intensive care unit.

Authors:  Thanh N Huynh; S Sam Weigt; John A Belperio; Mary Territo; Michael P Keane
Journal:  J Transplant       Date:  2009-09-15

8.  Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era.

Authors:  Isaline Coquet; Juliette Pavie; Pierre Palmer; François Barbier; Stéphane Legriel; Julien Mayaux; Jean Michel Molina; Benoît Schlemmer; Elie Azoulay
Journal:  Crit Care       Date:  2010-06-09       Impact factor: 9.097

9.  CCC meets ICU: redefining the role of critical care of cancer patients.

Authors:  Michael von Bergwelt-Baildon; Michael J Hallek; Alexander A Shimabukuro-Vornhagen; Matthias Kochanek
Journal:  BMC Cancer       Date:  2010-11-08       Impact factor: 4.430

10.  Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: a secondary analysis of the ICNARC Case Mix Programme Database.

Authors:  Peter A Hampshire; Catherine A Welch; Lawrence A McCrossan; Katharine Francis; David A Harrison
Journal:  Crit Care       Date:  2009-08-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.